日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The landscape and evolution of clonal hematopoiesis in chronic lymphocytic leukemia

慢性淋巴细胞白血病中克隆性造血的格局和演变

Al-Sawaf, Othman; Locher, Benjamin N; Christen, Friederike; Hablesreiter, Raphael; Rajamani, Anantharamanan; Robrecht, Sandra; Zhang, Can; Fink, Anna Maria; Tausch, Eugen; Schneider, Christof; Ritgen, Matthias; Kreuzer, Karl-Anton; Kopp, Klara; Mertz, Marie-Elisa; Fustero-Torre, Coral; Kleo, Karsten; Seymour, John; Blombery, Piers; Bullinger, Lars; Chyla, Brenda; Jin, Hyun Yong; Jiang, Yanwen; Stilgenbauer, Stephan; Hallek, Michael; Eichhorst, Barbara; Langerbeins, Petra; Fischer, Kirsten; Damm, Frederik

Analysis of Patients With Monocytic and Monocytic-Like Acute Myeloid Leukemia, Including AML-M4 and AML-M5, Treated With Venetoclax Plus Azacitidine

对接受维奈托克联合阿扎胞苷治疗的单核细胞和单核细胞样急性髓系白血病(包括 AML-M4 和 AML-M5)患者进行分析

Konopleva, Marina; DiNardo, Courtney D; Sun, Yan; Jung, Paul; Loghavi, Sanam; Potluri, Jalaja; Dail, Monique; Chyla, Brenda; Pollyea, Daniel A

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy

对不适合接受强化化疗的急性髓系白血病患者进行低剂量阿糖胞苷和维奈托克治疗的风险分层

Wei, Andrew H; Panayiotidis, Panayiotis; Montesinos, Pau; Laribi, Kamel; Ivanov, Vladimir; Kim, Inho; Novak, Jan; Champion, Rebecca; Fiedler, Walter; Pagoni, Maria; Bergeron, Julie; Ting, Stephen B; Hou, Jing-Zhou; Yamauchi, Takahiro; Wang, Jianxiang; Strickland, Stephen A; Savona, Michael R; Lin, Tara L; Enjeti, Anoop; Tiong, Ing Soo; Lee, Sangmin; Roboz, Gail J; Popovic, Relja; Jiang, Qi; Liu, Zihuan; Sun, Yan; Mendes, Wellington; Chyla, Brenda; DiNardo, Courtney D

Efficacy and safety of fixed-duration venetoclax plus obinutuzumab in untreated Japanese CLL and SLL: a phase 2 study

维奈托克联合奥妥珠单抗固定疗程治疗未经治疗的日本慢性淋巴细胞白血病和小淋巴细胞淋巴瘤的疗效和安全性:一项 II 期研究

Izutsu, Koji; Watanabe, Mitsumasa; Toubai, Tomomi; Tsukamoto, Taku; Maruyama, Dai; Kumode, Takahiro; Fukuhara, Noriko; Ogawa, Natsumi; Satomi, Natsuko; Nishimura, Yasuko; Honda, Hideyuki; Chyla, Brenda; Takizawa, Jun

A phase 2 study of ibrutinib with venetoclax in Japanese patients with untreated CLL and SLL

一项针对未经治疗的慢性淋巴细胞白血病 (CLL) 和小淋巴细胞淋巴瘤 (SLL) 日本患者的 II 期研究,评估伊布替尼联合维奈克拉的疗效。

Takizawa, Jun; Yoshida, Isao; Ogawa, Yoshiaki; Toubai, Tomomi; Kusumoto, Shigeru; Watanabe, Mitsumasa; Ogawa, Natsumi; Satomi, Natsuko; Nishimura, Yasuko; Honda, Hideyuki; Chyla, Brenda; Izutsu, Koji

Narrative Review of Opioid Use Disorder Treatment Changes During the COVID-19 Pandemic and Their Impact on American Indian/Alaska Native Communities

新冠疫情期间阿片类药物使用障碍治疗变化及其对美国印第安人/阿拉斯加原住民社区的影响的叙述性综述

Bingham-Hendricks, Chyla; Peters-Mosquera, Autaquay; Aronowitz, Shoshana V; Woods, Cedric; Aronowitz, Teri

Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes

维奈托克联合阿扎胞苷治疗初治高危骨髓增生异常综合征患者的疗效和安全性

Garcia, Jacqueline S; Platzbecker, Uwe; Odenike, Olatoyosi; Fleming, Shaun; Fong, Chun Yew; Borate, Uma; Jacoby, Meagan A; Nowak, Daniel; Baer, Maria R; Peterlin, Pierre; Chyla, Brenda; Wang, Huipei; Ku, Grace; Hoffman, David; Potluri, Jalaja; Garcia-Manero, Guillermo

The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL

MURANO 研究:VenR 治疗复发/难治性 CLL 患者的最终分析和再治疗/交叉亚组研究结果

Kater, Arnon P; Harrup, Rosemary; Kipps, Thomas J; Eichhorst, Barbara; Owen, Carolyn J; Assouline, Sarit; Lamanna, Nicole; Robak, Tadeusz; de la Serna, Javier; Jaeger, Ulrich; Cartron, Guillaume; Montillo, Marco; Mellink, Clemens; Langerak, Anton W; Chyla, Brenda; Popovic, Relja; Jiang, Yanwen; Millen, Rosemary; Lefebure, Marcus; Thadani-Mulero, Maria; Boyer, Michelle; Seymour, John F

Retreatment with venetoclax and rituximab following disease progression while off therapy in patients with chronic lymphocytic leukemia

慢性淋巴细胞白血病患者停药后疾病进展,可使用维奈托克和利妥昔单抗进行再治疗

Brander, Danielle M; Roberts, Andrew W; Kipps, Thomas J; Ma, Shuo; Anderson, Mary Ann; Boyer, Michelle; Blombery, Piers; Popovic, Relja; Roser, Jordan; Liu, Zhuangzhuang; Chyla, Brenda; Seymour, John F

Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment Consortium

可测量残留病灶(MRD)作为急性髓系白血病(AML)临床药物审批的替代终点:来自 MRD 合作组织和 AML 临床治疗联盟的观点

Boyiadzis, Michael; Wei, Andrew H; Paiva, Bruno; Freeman, Sylvie D; Kaspers, Gertjan; Chyla, Brenda; Hersey, Sarah; Patel, Reshma; Maloney, Brian; Blanchet Zumofen, Marie-Helene; Van Hoef, Marlies; Wulff, Beate; Obourn, Vanessa; Patel, Shalaka; Lopes de Menezes, Daniel; Shi, Qian; Bengoudifa, Bourras-Rezki; Dimier, Natalie; Prior, Thomas J; Roboz, Gail J; Prebet, Thomas